Polymer–drug conjugates (PDC) have exhibited clinical and commercial success in the field of drug delivery. A polymeric backbone, linker, targeting moiety, and drug constitute the building blocks of PDCs. Current attention is focusing on natural polymeric carriers, in particular the concept of graft copolymers, such as a combination of polymers and polysaccharides, to explore dual benefits such as combined vehicles and targeting moieties. Polymer heterogeneity, synthesis of PDCs, broad molecular weight distribution, conjugate variability, immunogenicity of polymers, safety, stability, and stringent regulatory approval are the major obstacles to the successful transition of PDCs to the clinic. In this review, we discuss natural and synthetic PDCs combined with computational modeling for diverse pharmaceutical and biomedical applications.

聚合物-药物偶联物 (PDC) 在药物递送领域取得了临床和商业上的成功。聚合物骨架、接头、靶向部分和药物构成了 PDC 的构建块。目前的注意力集中在天然聚合物载体上，特别是接枝共聚物的概念，例如聚合物和多糖的组合，以探索双重好处，例如组合载体和靶向部分。聚合物异质性、PDCs 的合成、广泛的分子量分布、共轭可变性、聚合物的免疫原性、安全性、稳定性和严格的监管批准是 PDCs 成功过渡到临床的主要障碍。在这篇综述中，我们讨论了天然和合成的 PDC 与计算建模相结合，适用于各种制药和生物医学应用。